Cell Reports vs PLOS ONE in 2026: When Selectivity Matters and When It Doesn't
Both are open-access biology journals, but Cell Reports is selective while PLOS ONE is inclusive. Learn which one fits your work and career stage.
Journal fit
See whether this paper looks realistic for Cell Reports.
Run the Free Readiness Scan with Cell Reports as your target journal and see whether this paper looks like a realistic submission.
Cell Reports at a glance
Key metrics to place the journal before deciding whether it fits your manuscript and career goals.
What makes this journal worth targeting
- Cell Reports's scope and readership determine whether the journal is a useful target.
- Scope specificity matters more than headline metrics for most manuscript decisions.
- Manusights has not verified a current acceptance rate for Cell Reports. Check the publisher source for current data; this does not mean the publisher reports none.
When to look elsewhere
- When your paper sits at the edge of the journal's stated scope, borderline fit rarely improves after submission.
- If timeline matters: Cell Reports takes 5 days median. A faster-turnaround journal may suit a grant or job deadline better.
- If OA is required: gold OA costs $5,790 USD. Check institutional agreements before submitting.
Cell Reports vs PLOS ONE at a glance
Use the table to see where the journals diverge before you read the longer comparison. The right choice usually comes down to scope, editorial filter, and the kind of paper you actually have.
Question | Cell Reports | PLOS ONE |
|---|---|---|
Best fit | Cell Reports publishes peer-reviewed research across the entire life sciences spectrum.. | PLOS ONE says it publishes original research, methods, software, databases, qualitative. |
Editors prioritize | New biological insight, period | Methodological rigor above all else |
Typical article types | Report, Article | Research Article, Registered Report |
Closest alternatives | eLife, Nature Communications | Scientific Reports, PeerJ |
Quick answer, acceptance-rate source check (October 21, 2026): We have not verified a current acceptance rate for Cell Reports. Check Elsevier’s journal catalog for the publisher’s current figure; an unverified figure does not mean the publisher reports none. Elsevier journal catalog.
Quick verdict: Choose Cell Reports when your paper has genuine mechanistic novelty in cell or molecular biology and you need the career signal.
Choose PLOS ONE when the work is technically rigorous but the novelty argument is weak, and you need it published without a lengthy rejection cycle.
This comparison isn't about journal quality. It's about two fundamentally different editorial models. Cell Reports selects for novelty and mechanistic depth. PLOS ONE selects for technical soundness. Neither model is wrong, but submitting to the wrong one wastes months.
Head-to-head comparison
Metric | Cell Reports | PLOS ONE |
|---|---|---|
2025 JIF (2026 JCR release) | 7.7 | 2.8 |
5-year JIF | ~8.0 | 3.2 |
APC | $5,790 | $2,477 |
Desk decision time | ~5 days | Variable |
Median time to first decision | 5 days (first editorial decision) | 32 days (2025) |
Total submission to publication | No published figure (unofficial estimate: ~31 weeks) | 209 days (2025 median) |
Papers per year | No published count (unofficial estimate: ~1,000) | 18,300 (2025) |
Publisher | Cell Press (Elsevier) | PLOS |
Scope | Life sciences | All sciences |
Review model | Novelty + technical soundness | Technical soundness only |
Quartile | Q1 (Cell Biology) | Q2 (Multidisciplinary) |
Journal fit
Ready to find out which journal fits? Run the scan for Cell Reports first.
Run the scan with Cell Reports as the target. Get a fit signal that makes the comparison concrete.
What each journal actually evaluates
Understanding the editorial model is more useful than comparing impact factors.
Cell Reports says the primary criterion for publication is new biological insight. Editors look for a clear biological story with experimental evidence showing how something works at the cellular or molecular level. Descriptive work without a mechanism doesn't fit. Characterization studies without functional follow-up get desk-rejected. Cell Reports reports a median of 5 days to a first editorial decision, so authors learn quickly whether a paper fits their scope.
PLOS ONE asks: "Is this research technically sound?" The journal evaluates methodology, data quality, reproducibility, and whether conclusions are supported by evidence. It explicitly does not evaluate for perceived importance, novelty, or whether the findings will change the field. This isn't a lower standard, it's a different standard.
Where Cell Reports wins
Career signal in biology. A Cell Reports publication tells hiring committees and grant reviewers that your work was evaluated for novelty by Cell Press editors. For faculty searches in cell biology, developmental biology, or molecular biology, this distinction matters. Hiring committees understand the difference between journals that gate on novelty and journals that gate on soundness.
The Cell Press transfer system. Papers rejected from Cell, Molecular Cell, Cell Stem Cell, or other Cell Press titles can transfer to Cell Reports with reviews intact. This saves 2-3 months of re-review time. If you're aiming at Cell and the editors say "strong but not broad enough," Cell Reports is the built-in landing spot.
JIF leverage. At 6.9, Cell Reports sits above the threshold that many grant agencies and promotion committees treat as "high-impact." In many institutional metrics systems, 6.9 and 2.6 fall on different sides of a meaningful line.
Field-specific audience. Cell Reports' roughly 1,000 papers per year (an unofficial estimate) means each paper gets more relative attention within the cell biology community. PLOS ONE's 18,300 papers in 2025 means higher competition for attention, even with good indexing.
Where PLOS ONE wins
Cost. PLOS ONE's APC is $2,477, less than half of Cell Reports' $5,790. For researchers who need a cost their lab can absorb without institutional OA agreements, PLOS ONE is dramatically more accessible.
No novelty requirement. This is the central philosophical difference. PLOS ONE publishes negative results, replication studies, methodological validations, and incremental but rigorous contributions. These papers are scientifically valuable but don't survive novelty-gated journals. Forcing a novelty argument onto work that doesn't naturally have one usually makes the paper weaker, not stronger.
Broader scope. PLOS ONE accepts work across all scientific disciplines. Interdisciplinary papers that don't fit a single-discipline journal's scope have a natural home. Cell Reports is limited to the life sciences.
Institutional fee coverage. PLOS has agreements with many universities and library systems that eliminate or reduce the APC. PLOS offers a "Flat Fee" agreement under which an institution pays an annual flat fee and its authors can publish in PLOS ONE at no cost to the authors. Check whether your institution has a PLOS agreement before comparing sticker prices.
Declining stigma. PLOS ONE's reputation has improved significantly since the early mega-journal era. A PLOS ONE publication in 2026 carries more weight than the same publication in 2016.
The career stage calculation
For a postdoc competing for faculty positions: Cell Reports is worth the extra time and cost if the novelty argument holds. A Cell Press publication signals competitive research to search committees. If the novelty argument is borderline, though, a 3-month rejection cycle at Cell Reports followed by resubmission to PLOS ONE costs more career time than going directly to PLOS ONE.
For a mid-career researcher: Publishing a dataset, methodological comparison, or follow-up study in PLOS ONE is the pragmatic choice. The career signal of Cell Reports matters less when your CV already demonstrates competitiveness. Getting the work published efficiently matters more.
For a graduate student: If this paper will be part of your thesis and your advisor agrees the novelty is there, Cell Reports is worth trying. If the paper is your third or fourth chapter and you need it published to defend, PLOS ONE's soundness-only review may be more valuable than the IF difference.
Common mistakes
Submitting to Cell Reports without a mechanistic story. The most common rejection pattern: a well-executed characterization study that describes what happens but doesn't explain why. "We profiled the transcriptome of X and found Y" is a PLOS ONE paper unless you also show the mechanism behind Y. Cell Reports editors recognize this pattern quickly and desk-reject early.
Dismissing PLOS ONE as "not good enough." Some advisors still carry the stigma of early mega-journals. A technically excellent paper in PLOS ONE is better for your career than a stretched novelty claim that gets rejected from Cell Reports and delays publication by 6 months.
Not checking institutional OA agreements. Cell Reports at $5,790 and PLOS ONE at $2,477 are both sticker prices. Your institution may have agreements that change the math entirely. PLOS's "Flat Fee" agreements eliminate APCs for authors at participating institutions. Elsevier has transformative agreements covering Cell Press journals at many universities. Check your library's OA page before choosing based on cost.
Submit to Cell Reports when
- The paper has a clear mechanistic story in cell or molecular biology
- You can articulate what the reader learns about how something works
- The Cell Press transfer system is relevant (you're already in that ecosystem)
- The career signal matters (faculty search, grant application, tenure case)
- Your institution covers the $5,790 APC through an OA agreement
Submit to PLOS ONE when
- The work is technically rigorous but the novelty argument is honest-to-God borderline
- You're publishing negative results, replication data, or methodological work
- The paper is interdisciplinary and doesn't fit a single-discipline scope
- Cost matters more than the IF signal
- You want published median timings to plan around (32 days to first decision and 209 days to publication in 2025)
- Your institution has a PLOS "Flat Fee" agreement that eliminates the APC
The right sequence for uncertain papers
If you're not sure which journal fits, this order saves the most time:
- Run the Cell Reports vs. PLOS ONE scope check to assess whether the novelty argument holds
- If the scan flags novelty as a weakness, go directly to PLOS ONE
- If novelty scores well, try Cell Reports first, noting that Cell Press reports a median of 5 days to a first editorial decision
- If Cell Reports rejects, reformat for PLOS ONE, you've lost 1-2 weeks, not months
A Cell Reports vs. PLOS ONE scope check takes about two to three minutes and prevents the most common mistake: spending 3 months in Cell Reports review only to end up at PLOS ONE anyway.
Frequently asked questions
Check the publisher catalog for a current acceptance rate. PLOS ONE reports 26% for 2025. But the real difference is what they select for: Cell Reports' primary criterion is new biological insight. PLOS ONE requires only technical soundness and reproducibility, regardless of novelty.
No. PLOS ONE is one of the largest scientific journals in the world by volume. It publishes technically sound research without requiring novelty claims. The IF of 2.6 reflects its inclusive editorial model, not poor quality. For solid work that doesn't make a novelty argument, PLOS ONE is a legitimate and well-indexed option.
Cell Reports charges $5,790 APC. PLOS ONE charges $2,477. Both are gold open access. Many institutions have agreements that reduce or eliminate the PLOS ONE fee. The $3,313 difference is the largest cost gap in this comparison.
If the work has genuine mechanistic novelty, yes. Cell Reports carries more weight on a CV for competitive positions. If the work is solid but the novelty argument is weak, PLOS ONE avoids a lengthy rejection cycle that costs time early-career researchers can't afford.
PLOS ONE reports a median of 32 days to first decision and 209 days to publication (2025). Cell Reports reports a median of 5 days to a first editorial decision (which includes desk decisions) and 22 days from acceptance to online publication. Cell Press publishes no submission-to-publication median for Cell Reports, so the two cannot be compared end to end on official figures.
Sources
- Cell Reports Author Guidelines
- Cell Reports APC and Publishing Options
- PLOS ONE Journal Information
- PLOS Publication Fees
- Clarivate Journal Citation Reports (2026 release for the 2025 Journal Impact Factor)
Final step
See whether this paper fits Cell Reports.
Run the Free Readiness Scan with Cell Reports as your target journal and get a manuscript-specific fit signal before you commit.
Target journal Cell Reports
Private API processing. Your manuscript is not used to train models.
See example reportsPut the guidance to work
Build a journal decision from more than one signal.
Use comparison data as a starting point, then confirm the live source that governs the actual submission decision.